Amoxicilline/clavulanic — Competitive Intelligence Brief

Amoxicilline/clavulanic (Amoxicilline/clavulanic) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic with beta-lactamase inhibitor. Area: Infectious Disease.

phase 3 Beta-lactam antibiotic with beta-lactamase inhibitor Bacterial penicillin-binding proteins; bacterial beta-lactamases Infectious Disease Small molecule

Target snapshot

Amoxicilline/clavulanic (Amoxicilline/clavulanic) — Bayer. Amoxicillin/clavulanic acid is a beta-lactam antibiotic combination that kills bacteria by inhibiting cell wall synthesis, with clavulanic acid protecting amoxicillin from degradation by bacterial beta-lactamases.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Amoxicilline/clavulanic TARGET	Amoxicilline/clavulanic	Bayer	phase 3	Beta-lactam antibiotic with beta-lactamase inhibitor	Bacterial penicillin-binding proteins; bacterial beta-lactamases
Sulbactam Sodium/Ampicillin Sodium	Sulbactam Sodium/Ampicillin Sodium	Pfizer	phase 3	Beta-lactam antibiotic with beta-lactamase inhibitor	Bacterial penicillin-binding proteins; bacterial beta-lactamases
Amoxycillin/clavulanic acid	Amoxycillin/clavulanic acid	TASK Applied Science	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamase
Co-amoxiclav	Co-amoxiclav	Imperial College London	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Bacterial penicillin-binding proteins (PBPs); bacterial beta-lactamases
ampicillin/clavulanate	ampicillin/clavulanate	Phoenix Children's Hospital	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamases
Imipenem+Relebactam	Imipenem+Relebactam	Wake Forest University Health Sciences	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (imipenem); serine beta-lactamases (relebactam)
Amoxicillin and Clavulanic Acid	Amoxicillin and Clavulanic Acid	Maggiore Bellaria Hospital, Bologna	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamases

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic with beta-lactamase inhibitor class)

1. Medical University of Vienna · 2 drugs in this class
2. GlaxoSmithKline · 2 drugs in this class
3. Phoenix Children's Hospital · 2 drugs in this class
4. Albany Medical College · 2 drugs in this class
5. Pfizer · 2 drugs in this class
6. Imperial College London · 1 drug in this class
7. Hospital Italiano de Buenos Aires · 1 drug in this class
8. Bayer · 1 drug in this class
9. Maggiore Bellaria Hospital, Bologna · 1 drug in this class
10. Kaizen Bioscience Co. · 1 drug in this class